Galmed Pharmaceuticals Ltd. has announced promising results from pre-clinical studies of their drug Aramchol, which shows significant anti-fibrotic effects in models of primary sclerosing cholangitis $(PSC.AU)$. Aramchol, an SCD1 inhibitor, demonstrated the ability to attenuate and prevent biliary fibrosis in mouse models of PSC, significantly inhibiting TGFβ-induced hepatic fibrosis pathways and upregulating PPAR signaling. These pre-clinical findings provide a strong rationale for further clinical trials, particularly in patients suffering from fibrosis-driven liver cancers. Galmed's President and CEO, Allen Baharaff, emphasized the potential for Aramchol to advance into Phase 2/3 clinical studies, given its robust anti-fibrotic effects previously observed in clinical studies with NASH and advanced fibrosis patients. This development marks a significant step forward in addressing the urgent need for effective treatments for biliary fibrosis and related liver conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.